

ALKERMES INC
Form 8-K
November 02, 2007

Table of Contents

**SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

**FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): October 31, 2007
ALKERMES, INC.
(Exact Name of Registrant as Specified in its Charter)**

PENNSYLVANIA
(State or Other Jurisdiction of
Incorporation)

1-14131
(Commission
File Number)

23-2472830
(I.R.S. Employer
Identification No.)

88 Sidney Street
Cambridge, Massachusetts
(Address of principal executive offices)

02139
(Zip Code)

Registrant's telephone number, including area code: **(617) 494-0171**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

TABLE OF CONTENTS

Item 8.01 Other Events

Item 9.01 Financial Statements and Exhibits

SIGNATURE

EXHIBIT INDEX

EX-99.1 Press release issued by Alkermes, Inc., dated October 31, 2007

Table of Contents

Item 8.01 Other Events

On October 31, 2007, Alkermes, Inc. issued a press release announcing positive results from a 30-week comparator study of once-weekly exenatide long-acting release (LAR) injection and BYETTA® (exenatide) injection taken twice daily in patients with type 2 diabetes.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No. Description

99.1 Press release issued by Alkermes, Inc. dated October 31, 2007 announcing positive results from a 30-week comparator study of once-weekly exenatide long-acting release (LAR) injection and BYETTA® (exenatide) injection taken twice daily in patients with type 2 diabetes.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALKERMES, INC.

Date: November 2, 2007

By: /s/ James M. Frates
James M. Frates
Senior Vice President, Chief Financial
Officer and Treasurer (Principal
Financial and Accounting Officer)

Table of Contents

EXHIBIT INDEX

- 99.1 Press release issued by Alkermes, Inc. dated October 31, 2007 announcing positive results from a 30-week comparator study of once-weekly exenatide long-acting release (LAR) injection and BYETTA® (exenatide) injection taken twice daily in patients with type 2 diabetes.